Tube shunt surgery is a procedure that lowers eye pressure in glaucoma by implanting a tiny silicone tube that drains fluid from inside the eye to a small plate sutured to the eyeball’s surface. The tube acts as a permanent channel, redirecting fluid away from the eye’s natural drainage system and toward a reservoir that forms around the plate, where the fluid is gradually absorbed by surrounding tissue. Once reserved for the toughest cases where other surgeries had failed, tube shunts have become one of the most common glaucoma operations worldwide, and the evidence behind them has grown considerably over the past two decades.
How a Tube Shunt Works
The basic design traces back to the Molteno implant, which established the blueprint still used today: a silicone tube creates a permanent opening through the eye wall, while a plate positioned farther back on the eye determines the area of a fluid-filled pocket called a bleb. By moving the bleb away from the front of the eye and toward the equatorial region, the design avoids many of the scarring problems that plague procedures performed right at the limbus, the border where the cornea meets the white of the eye.1PubMed Central. Aqueous shunt implantation in glaucoma Fluid drains through the tube, pools around the plate under the conjunctiva, and is absorbed into surrounding blood vessels and lymphatic channels. Over several weeks, a fibrous capsule naturally forms around the plate. The thickness and permeability of that capsule largely determine how well the implant controls pressure long-term.
The Main Implant Types
Two families of tube shunts dominate clinical practice: nonvalved devices like the Baerveldt, and valved devices like the Ahmed Glaucoma Valve. The distinction matters because it shapes both the surgical approach and what happens during recovery.
The Ahmed valve contains a built-in flow restrictor, a small membrane mechanism that limits how much fluid drains in the early postoperative period. This means pressure tends to drop quickly after surgery, and the risk of dangerously low pressure (hypotony) in the first days is reduced. The trade-off is a higher rate of bleb encapsulation, where the fibrous capsule around the plate thickens and chokes off drainage. In one head-to-head comparison, roughly 60% of Ahmed patients developed clinical bleb encapsulation compared with about 27% of Baerveldt patients, and the encapsulation appeared sooner after surgery in the Ahmed group.2PubMed. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma: a single-surgeon comparison of outcome
The Baerveldt, by contrast, has no valve. Because it would drain too freely right after implantation, surgeons tie a dissolving suture around the tube to block flow temporarily, then create small holes (fenestrations) or nylon wicks to allow a trickle of fluid through until the suture dissolves weeks later and full drainage begins. At five years, the major Ahmed-versus-Baerveldt trial found that Baerveldt patients had a lower failure rate and lower eye pressure on fewer medications, though they carried a small risk of hypotony that was essentially absent in the Ahmed group.3PubMed. The Ahmed Versus Baerveldt Study: Five-Year Treatment Outcomes The choice between them often comes down to how much early hypotony a surgeon is willing to manage versus how much long-term encapsulation they want to avoid.
How Tube Shunts Compare to Trabeculectomy
Trabeculectomy, a procedure that creates a small flap in the eye wall to let fluid escape, has been the gold-standard glaucoma surgery for decades. The Tube Versus Trabeculectomy (TVT) study was the first large randomized trial comparing the two in patients who had already had cataract surgery or a failed trabeculectomy. It found that tube shunts had a notably higher success rate over three years: the probability of failure was about 15% in the tube group versus roughly 31% in the trabeculectomy group.4PubMed Central. Review of Results from the Tube Versus Trabeculectomy (TVT) Study That study reshaped practice for eyes with prior surgery.
The picture looks different in eyes that haven’t been operated on before. The Primary Tube Versus Trabeculectomy (PTVT) study randomized patients with no prior eye surgery and found that at one year, trabeculectomy actually outperformed tubes, with a failure rate of about 8% compared with 17% for tubes. By three and five years, though, the gap narrowed and the differences were no longer statistically significant, reaching roughly 28% versus 33% at three years and 35% versus 42% at five years.5PubMed Central. Results from the Primary Tube Versus Trabeculectomy Study and Translation to Clinical Practice In other words, trabeculectomy may offer better early results in a pristine eye, but tubes catch up over time, and in previously operated eyes, tubes tend to hold up better.
When researchers have measured patient-reported quality of life using a validated vision questionnaire, the two procedures showed similar impact.6PubMed. Quality of Life in the Tube Versus Trabeculectomy Study Neither one seems to leave patients feeling substantially better or worse about their day-to-day vision than the other, which reinforces that the decision is usually driven by the clinical specifics of the eye rather than by overall patient experience.
What Happens During the Procedure
Tube shunt surgery is typically performed under local anesthesia, either with an injection behind the eye or, in some cases, with topical numbing drops alone. The surgeon opens the conjunctiva in one quadrant of the eye, usually the upper-outer area, and tucks the plate beneath the eye muscles before stitching it to the eyeball’s surface. For a Baerveldt-type device, the surgeon identifies two adjacent rectus muscles using hooks and slides the plate’s wings under them. The tube is trimmed to the right length and inserted into the eye through a tiny needle track about one to two millimeters behind the limbus.7Journal of Glaucoma. A Comparison of Retrobulbar Versus Topical Anesthesia in Trabeculectomy and Aqueous Shunt Surgery
With nonvalved devices, the surgeon ties a dissolving suture around the tube to prevent immediate overdrainage. To let some fluid through while the suture is intact, small fenestrations are made in the tube, or nylon threads called wicks are threaded through slots in the tube wall anterior to the ligature. One study compared fenestrations alone with fenestrations plus two nylon wicks in Baerveldt and ClearPath implants, all ligated with a dissolving suture, to evaluate early pressure control.8Journal of Glaucoma. Effect of Nylon Wick Technique on Early Intraocular Pressure Control in Nonvalved Aqueous Shunt Surgery The goal is a controlled trickle that keeps pressure from spiking during the weeks it takes for the capsule around the plate to mature enough to handle full flow.
Where the Tube Can Be Placed
Most tube shunts enter the front chamber of the eye, just behind the cornea. But this is not the only option. In some patients, especially those with corneal problems, prior surgery, or an artificial lens that makes the front chamber tricky to navigate, the tube can be placed in the sulcus (the groove behind the iris) or through the pars plana (a region farther back, behind the lens). A retrospective study from Massachusetts Eye and Ear evaluated outcomes of all three placement sites, selecting 40 patients per group.9PubMed Central. Outcomes of Anterior Chamber, Sulcus, and Pars Plana Glaucoma Drainage Device Placement in Glaucoma Patients Each approach has trade-offs. Anterior chamber tubes sit close to the cornea’s inner lining and can accelerate loss of corneal cells. Pars plana placement requires simultaneous vitrectomy surgery, adding complexity. Sulcus placement offers a middle ground but depends on the patient having a lens implant to shield the tube from the iris.
Covering the Tube with a Patch Graft
Where the tube crosses the eye wall, it lies just beneath the thin conjunctival tissue. Without reinforcement, the tube can erode through the surface over time, creating a path for infection. Surgeons place a patch graft over this vulnerable spot, and the choice of graft material turns out to matter more than you might expect.
Donor sclera, the tough white coating of a human donor eye, has been a longstanding choice. Bovine pericardium, processed tissue from cow heart lining, became popular as a convenient off-the-shelf alternative. But one study found a stark difference: about 14% of eyes grafted with bovine pericardium developed tube exposure, compared with none in the donor sclera group.10PubMed Central. Donor sclera versus bovine pericardium as patch graft material in glaucoma implant surgery and the impact of a drainage suture Partial-thickness corneal tissue has also been evaluated as a patch graft, with favorable long-term results and low rates of exposure.11PubMed Central. Partial thickness corneal tissue as a patch graft material for prevention of glaucoma drainage device exposure Even scleral grafts are not immune to problems; they can thin gradually over the months and years after surgery, with the most dramatic thinning occurring after about 12 months.12PubMed. Scleral Patch Graft Melt After Tube Shunt Surgery: Grading and Identification of Risk Factors
Conjunctival erosion, when the surface tissue breaks down and exposes the tube or plate, occurred in about 7.5% of eyes in one large series of Ahmed valve patients. Certain factors increased the risk: absence of the natural lens (aphakia), inflammatory glaucoma, and prolonged postoperative steroid use.13PubMed Central. Factors Associated with Conjunctival Erosions after Ahmed Glaucoma Valve Implantation When exposure does occur, repair surgery is necessary, and the outcomes depend on the specifics. One study found that repositioning the tube during repair eliminated recurrence entirely in those cases, while a shorter interval between the original surgery and the repair, a history of prior revisions, and the use of human pericardial donor patches at revision were all associated with higher recurrence rates.14PubMed Central. Aqueous shunt exposure repair: outcomes and risk factors for recurrence
The Hypertensive Phase
One of the more confusing aspects of recovery for patients is the hypertensive phase, a period during the first three months when eye pressure can rise despite the implant being in place. This happens because the fibrous capsule forming around the plate goes through a stage where it is relatively thick and tight, resisting the outflow of fluid. It is more common with valved devices like the Ahmed, which begin draining immediately and trigger an earlier capsule response. The type of device, its material, and the surface area of the plate all influence how likely and how severe this pressure spike is.15PubMed Central. Etiology and management of the hypertensive phase in glaucoma drainage-device surgery During this phase, you may need to go back on glaucoma eye drops temporarily, or your surgeon may massage the bleb or perform a minor procedure to keep pressure under control until the capsule matures and becomes more permeable.
Long-Term Concerns for the Cornea
The inner surface of the cornea is lined with a layer of cells called the endothelium that keeps the cornea clear. These cells do not regenerate, so any ongoing loss eventually threatens vision. Because the tube sits inside the eye, often in the front chamber just behind the cornea, it can cause a slow but steady decline in endothelial cell counts.
Research on Ahmed valves found that tubes placed in the front chamber caused about twice the monthly endothelial cell loss compared with tubes placed in the sulcus. Younger age and front-chamber placement were the strongest predictors of faster loss.16PubMed Central. The Effect of Tube Location on Corneal Endothelial Cells in Patients with Ahmed Glaucoma Valve A separate study drilling into the physical parameters found that the distance from the tip of the tube to the cornea was the single most important modifiable factor: the closer the tube sat to the inner corneal surface, the faster cells were lost.17PubMed. Effect of glaucoma tube shunt parameters on cornea endothelial cells in patients with Ahmed valve implants This is why surgeons try to position the tube with its tip well clear of the cornea, often aiming it parallel to the iris rather than pointing upward toward the corneal surface.
Eye Movement Problems After Surgery
Because the plate sits beneath or between the eye muscles, tube shunts can sometimes interfere with eye movement. In the first year of the TVT study, about 10% of tube patients developed a new or worsened motility disturbance, compared with none of the trabeculectomy patients.18PubMed Central. Motility disturbances in the tube versus trabeculectomy study during the first year of follow-up Double vision is the most common symptom. It can resolve on its own as swelling settles, but in some cases it persists and requires prism glasses or further surgery. This risk is higher with larger plate sizes and with plates tucked into tighter spaces between muscles.
Tube Shunts in Children
Pediatric glaucoma is rare but serious, and tube shunts are an important tool when angle surgery or trabeculectomy has failed. The challenges in children are different: their eyes are smaller and still growing, their tissue heals more aggressively (which means more scarring around implants), and they often need general anesthesia for every exam and adjustment.
In a study of children who had already undergone multiple prior surgeries, Ahmed tube implantation brought average eye pressure down from about 25 mmHg to about 18 mmHg, and the number of daily medications dropped from roughly three to roughly one. The success rate was 82% at a mean follow-up of just over four years, and complications were described as minor and transient.19PubMed. Long-term outcomes of Ahmed tube implantation in pediatric glaucoma after multiple surgeries When a first tube shunt fails in a child, the question becomes whether to place a second shunt or switch to a laser procedure called cyclophotocoagulation. One comparison found similar success rates between the two approaches at two years, though corneal decompensation was a concern in a substantial fraction of eyes receiving a second tube.20PubMed Central. Cyclophotocoagulation versus sequential tube shunt as a secondary intervention following primary tube shunt failure in pediatric glaucoma
What Happens When a Tube Shunt Fails
Tube shunts do not last forever. The most common reason for late failure is excessive scarring of the capsule around the plate, which strangles drainage. When this happens, surgeons have several options: restarting eye drops, performing needling of the capsule at the bedside, or doing a formal revision in the operating room.
Revision surgery typically involves cutting away the thick fibrous capsule and applying an antifibrotic agent like mitomycin C to discourage regrowth. A study comparing mitomycin C alone with mitomycin C plus a collagen matrix implant (ologen) found that three-year success rates were in the range of 52% to 67%, with no statistically significant difference between the two approaches. However, complications were much lower when the collagen matrix was added: 27% versus 75%. In the mitomycin-only group, a quarter of eyes developed plate erosion severe enough to require removal of the entire implant, a complication that did not occur in the collagen-matrix group.21Journal of Glaucoma. Tube Shunt Revision With Excision of Fibrotic Capsule Using Mitomycin C With and Without Ologen—a Collagen Matrix Implant: A 3-Year Follow-up Study Revision is clearly a less reliable proposition than the original surgery, which is why maximizing the lifespan of the first implant matters so much.
Medication Reduction After Surgery
For many patients, one of the most appealing aspects of tube shunt surgery is reducing the burden of daily eye drops. Glaucoma medications are expensive, require strict adherence, and often cause chronic eye surface irritation that worsens over years of use. After tube shunt surgery, the median number of daily glaucoma medications typically drops from about three preoperatively to about one at the one-year mark, and this reduction tends to persist over time.22Journal of Glaucoma. Systematic Occlusion of Shunts: Control of Early Postoperative IOP and Hypotony-related Complications Following Glaucoma Shunt Surgery Getting to zero medications is possible but not guaranteed; many patients still need one or two drops to keep pressure at their target.
Tube Shunts for Inflammatory Glaucoma
Uveitic glaucoma, where chronic inflammation inside the eye drives up pressure, poses a particular surgical challenge. Inflammation accelerates scarring, which works against any procedure that depends on a bleb. A systematic review and meta-analysis comparing trabeculectomy with tube shunts in uveitic glaucoma found comparable results for both pressure reduction and medication reduction.23PubMed. Effectiveness and Safety of Trabeculectomy Versus Tube Shunt Implantation for Uveitic Glaucoma: A Systematic Review and Meta-Analysis Many surgeons lean toward tubes in these eyes anyway, partly because the plate and capsule are set farther back from the inflammatory action at the front of the eye, and partly because tubes tend to tolerate the repeated inflammation flare-ups that make trabeculectomy blebs unpredictable.
Cost Considerations
Tube shunt surgery costs more upfront than trabeculectomy or medical therapy alone. A cost-effectiveness analysis modeled over five years found mean costs of roughly $6,200 for medical treatment, $7,900 for trabeculectomy, and $10,100 for tube insertion. But cost is only part of the equation: the probability of going blind over five years was about 4% for both surgical options versus 15% for medical treatment alone. When the analysis factored in quality-adjusted life years, both surgeries were cost-effective compared with drops alone. Tube insertion cost about $29,000 per additional quality-adjusted life year compared with trabeculectomy, a figure generally considered acceptable in healthcare economics.24PubMed. Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment For patients stuck on three or four expensive brand-name drops with worsening disease, the upfront cost of surgery may actually save money over the long run while providing better pressure control.
How Device Design Has Evolved
The modern era of glaucoma drainage implants began with a simple concept: a plate sutured behind the limbus, connected to the front of the eye by a silicone tube. From that starting point, two broad design philosophies emerged. Nonrestrictive devices like the Molteno and Baerveldt allow free flow once open, relying on external suture ligation for early pressure control. Flow-restrictive devices like the Ahmed use an internal valve mechanism to moderate drainage from the start. Over time, clinical experience drove iterative improvements in plate materials, surface textures, and implant profiles, gradually reducing complications and broadening the indications for surgery beyond just refractory cases.25PubMed Central. The Evolution of Glaucoma Drainage Implants Newer entries like the ClearPath implant continue to refine the nonvalved design, and microinvasive glaucoma surgery (MIGS) devices represent a parallel track of much smaller implants for milder disease, though they occupy a different clinical niche than traditional tube shunts and do not achieve the same magnitude of pressure reduction.